Rationale, design and population baseline characteristics of the PERFORM Vascular Project: an ancillary study of the Prevention of cerebrovascular and cardiovascular Events of ischemic origin with teRutroban in patients with a history oF ischemic strOke or tRansient ischeMic attack (PERFORM) trial

Sorbera LA(2006)Terutroban sodium. Prostanoid tp receptor antagonist, antithrombotic agent, antiatherosclerotic agent Drugs Future 31 867-73

Serradell N(2004)S18886, a new specific TP-receptor antagonist, is safe and as effective as aspirin in inhibiting platelet aggregation in patients with peripheral arterial disease Eur Heart J 25 573-18

Bolos J(2009)Rationale and design of a randomized, double-blind, parallel-group study of terutroban 30 mg/day versus aspirin 100 mg/day in stroke patients: the Prevention of cerebrovascular and cardiovascular Events of ischemic origin with teRutroban in patients with a history oF ischemic strOke or tRansient ischeMic attack (PERFORM) study Cerebrovasc Dis 27 509-13

Bayes M(2009)The Prevention of cerebrovascular and cardiovascular Events of ischemic origin with teRutroban in patients with a history oF ischemic strOke or tRansient ischeMic attack (PERFORM) study: baseline characteristics of the population Cerebrovasc Dis 27 608-41

Fiessinger JN(2002)Role of prostacyclin in the cardiovascular response to thromboxane A2 Science 296 539-8

Bousser MG(2000)The thromboxane receptor antagonist S18886 but not aspirin inhibits atherogenesis in apo E-deficient mice: evidence that eicosanoids other than thromboxane contribute to atherosclerosis Arterioscler Thromb Vasc Biol 20 1724-42

Amarenco P(2005)Cyclooxygenases, thromboxane, and atherosclerosis: plaque destabilization by cyclooxygenase-2 inhibition combined with thromboxane receptor antagonism Circulation 111 334-61

Chamorro A(2005)Atherosclerosis regression and TP receptor inhibition: effect of S18886 on plaque size and composition—a magnetic resonance imaging study Eur Heart J 26 1557-73

Bousser MG(2005)S18886, a selective TP receptor antagonist, inhibits development of atherosclerosis in rabbits Atherosclerosis 183 65-204

Amarenco P(2003)Improved endothelial function by the thromboxane A2 receptor antagonist S18886 in patients with coronary artery disease treated with aspirin J Am Coll Cardiol 41 1198-22

Sorbera LA(2006)Terutroban sodium. Prostanoid tp receptor antagonist, antithrombotic agent, antiatherosclerotic agent Drugs Future 31 867-73

Serradell N(2004)S18886, a new specific TP-receptor antagonist, is safe and as effective as aspirin in inhibiting platelet aggregation in patients with peripheral arterial disease Eur Heart J 25 573-18

Bolos J(2009)Rationale and design of a randomized, double-blind, parallel-group study of terutroban 30 mg/day versus aspirin 100 mg/day in stroke patients: the Prevention of cerebrovascular and cardiovascular Events of ischemic origin with teRutroban in patients with a history oF ischemic strOke or tRansient ischeMic attack (PERFORM) study Cerebrovasc Dis 27 509-13

Bayes M(2009)The Prevention of cerebrovascular and cardiovascular Events of ischemic origin with teRutroban in patients with a history oF ischemic strOke or tRansient ischeMic attack (PERFORM) study: baseline characteristics of the population Cerebrovasc Dis 27 608-41

Fiessinger JN(2002)Role of prostacyclin in the cardiovascular response to thromboxane A2 Science 296 539-8

Bousser MG(2000)The thromboxane receptor antagonist S18886 but not aspirin inhibits atherogenesis in apo E-deficient mice: evidence that eicosanoids other than thromboxane contribute to atherosclerosis Arterioscler Thromb Vasc Biol 20 1724-42

Amarenco P(2005)Cyclooxygenases, thromboxane, and atherosclerosis: plaque destabilization by cyclooxygenase-2 inhibition combined with thromboxane receptor antagonism Circulation 111 334-61

Chamorro A(2005)Atherosclerosis regression and TP receptor inhibition: effect of S18886 on plaque size and composition—a magnetic resonance imaging study Eur Heart J 26 1557-73

Bousser MG(2005)S18886, a selective TP receptor antagonist, inhibits development of atherosclerosis in rabbits Atherosclerosis 183 65-204

Amarenco P(2003)Improved endothelial function by the thromboxane A2 receptor antagonist S18886 in patients with coronary artery disease treated with aspirin J Am Coll Cardiol 41 1198-22